Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy
Condition: Nasopharyngeal Carcinoma Intervention: Drug: Anlotinib Sponsor: Sun Yat-sen University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials